EXEL vs REGN: fair value comparison
Exelixis, Inc. and Regeneron Pharmaceuticals, Inc. · Updated 2026-10-19
Both currently screen as fairly valued on TickrTrends' Forward Fair Value model. Within Healthcare, REGN currently sits closer to the top of our ranking by discount to fair value.
| EXEL | REGN | |
|---|---|---|
| Verdict | Fairly valued | Fairly valued |
| Last price | $62.23 | $746.54 |
| 12-month range | $37.90–$62.83 | $577.95–$852.03 |
| Rank by discount to fair value | #48 of 108 Healthcare | #46 of 108 Healthcare |
| Quality grade | A | A |
| Leverage | Low | Low |
| Margin trend | Stable | Stable |
| Revenue growth | Strong | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | — |
| DCF cross-check | Fairly Valued | Fairly Valued |
| 52-week position | The top quarter | The upper-middle quarter |
Full single-stock breakdowns: EXEL fair value analysis · REGN fair value analysis